Impact of Sodium-Glucose Co-Transporter Type-2 Inhibitors on Alanine Aminotransferase Levels in Type-2 Diabetes Patients Having Features of Nonalcoholic Fatty Liver Disease: A Retrospective Cohort Study in Pakistan

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2024 Dec 5

PMID 39634912

Authors

Asefa S Ansari

Azra Rizwan

Uzma Z Khan

Syed Iqbal Azam

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to elucidate the effectiveness of Sodium-glucose co-transporter-2 inhibitors (SGLT2-I) in the reduction of ALT among Type-2 diabetes patients (T2DM) with Non-alcoholic fatty liver disease (NAFLD).

Methods: We retrospectively collected data from 120 files of T2DM, aged 30-60 years, with elevated ALT, and documented follow-up for one year from August 2018 - July 2019. The effects of SGLT2Is (Dapagliflozin and Empagliflozin) were evaluated using Generalized Estimating Equation (GEE) for analysis.

Results: The overall mean age was 48.9 ± 7.3 years, 57.5% were females, and the mean duration of diabetes was 8.5 ± 5.6 years. At baseline, the mean BMI was 32.5 ± 5.7 kg/m, mean ALT was 51.6 IU/L ± 17.8 IU/L, and mean HbA1c was 8.5% ± 1.5%. There was a statistically significant reduction in mean ALT of 2.2 IU/L (p-value 0.02) with every 10 mg/dl increase in LDL among females using 10 mg Empagliflozin as compared to males not on SGLT2i.

Conclusions: We observed an average reduction in mean ALT levels when SGLT2Is was initiated in T2DM patients having NAFLD. Apart from encouraging diet and lifestyle modification, early intervention with SGLT2Is may decrease liver-related morbidity and mortality resulting from NAFLD.

References

Wong V, Chan W, Chitturi S, Chawla Y, Dan Y, Duseja A . Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2017; 33(1):70-85. DOI: 10.1111/jgh.13857. View

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall K, Ferrannini E . Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015; 38(9):1730-5. PMC: 4542276. DOI: 10.2337/dc15-0355. View

Afolabi B, Ibitoye B, Ikem R, Omisore A, Idowu B, Soyoye D . The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients. J Natl Med Assoc. 2018; 110(3):256-264. DOI: 10.1016/j.jnma.2017.06.001. View

Musso G, Cassader M, Rosina F, Gambino R . Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012; 55(4):885-904. DOI: 10.1007/s00125-011-2446-4. View

Pinidiyapathirage M, Dassanayake A, Rajindrajith S, Kalubowila U, Kato N, Wickremasinghe A . Non-alcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka. BMC Res Notes. 2011; 4:513. PMC: 3236075. DOI: 10.1186/1756-0500-4-513. View

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Osto E, Bonacina F, Pirillo A, Norata G . Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. Pharmacol Res. 2023; 188:106667. DOI: 10.1016/j.phrs.2023.106667. View

Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T . The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes. 2013; 11:138. PMC: 3751743. DOI: 10.1186/1477-7525-11-138. View

10.

Dassanayake A, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva A . Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol. 2009; 24(7):1284-8. DOI: 10.1111/j.1440-1746.2009.05831.x. View

11.

Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K . Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017; 40(10):1364-1372. DOI: 10.2337/dc17-0518. View

12.

Gautam A, Agrawal P, Doneria J, Nigam A . Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease. J Assoc Physicians India. 2019; 66(8):62-66. View

13.

Bechmann L, Emanuelsson F, Nordestgaard B, Benn M . SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2023; 394:117236. DOI: 10.1016/j.atherosclerosis.2023.117236. View

14.

Brener S . Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2015; 15(18):1-45. PMC: 4664937. View

15.

Plosker G . Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014; 74(18):2191-209. DOI: 10.1007/s40265-014-0324-3. View

16.

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

17.

Euh W, Lim S, Kim J . Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2021; 12:613389. PMC: 8222919. DOI: 10.3389/fendo.2021.613389. View

18.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

19.

Leiter L, Forst T, Polidori D, Balis D, Xie J, Sha S . Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2015; 42(1):25-32. DOI: 10.1016/j.diabet.2015.10.003. View

20.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View